Cohort study in chronic kidney disease patients on dialysis starting treatment with Mircera® to correct anemia or maintain stable hemoglobin levels FRESH-PEF74133-en Camille BACHOT Cohort study in chronic kidney disease patients on dialysis starting treatment with Mircera® to correct anemia or maintain stable hemoglobin levels HORTENSIA FRESH-PEF74133-en 74133 FRESH-PEF74133 NCT01213485 F. HOFFMANN-LA ROCHE AG Epidemiology France Portal (PEF) null ;Medical data center MIRCERA® Nephrology Chronic kidney disease Healthcare system determinants: Use of care Healthcare system determinants Primary objective: Describe the management of anemia treatment with Mircera® in routine clinical practice in chronic kidney disease patients on dialysis and to describe their hemoglobin concentration around the 6th month of treatment with Mircera®. Secondary objective: In the total population and in each sub-population of patients (hemodialysis and peritoneal dialysis, ESA-naive and non ESA-naive patients): 1. Describe the characteristics of patients treated with Mircera®; 2. Describe the evolution of Hb and hematocrit levels during the observation period; 3. Describe the biological parameters used to document renal anemia and any changes in values; 4. Describe the parameters influencing treatment response; 5. Describe the biological parameters reflecting the efficacy of dialysis; 6. Describe the safety profile of Mircera® (serious and/or unexpected adverse drug reactions and targeted adverse drug reactions related to Mircera®); 7. Describe treatment compliance with Mircera®; 8. Describe the evolution of patients’ quality of life, evaluated by the SF-36 questionnaire. null France Individuals Patients population Male Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Inclusion criteria: - Adult (aged >= 18 years); - With CKD and on dialysis for more than 3 months; - ESA-naive or not; - For whom the physician decided to initiate treatment with Mircera® for renal anemia at the inclusion visit; - Who was informed about the study both orally and in writing and who did not object to their personal data being processed. Patient participating in a clinical study; - Anemia due to a malignant disease. Clinical data Biological data CDISC GCP/GVP Health care consumption and services Other Through organizations (health services or institutions schools businesses etc.) < 500 individuals Other Observational Study Observational Study Cohort study 414 Unknown Restricted access Access on specific project only